(Q37018656)

17 August 2017

1 reference

title

NK cell receptors and their ligands in leukemia (English)

1 reference

17 August 2017

1 reference

Verheyden S

1

1 reference

17 August 2017

Demanet C

series ordinal

2

1 reference

17 August 2017

language of work or name

1 reference

29 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

22

1 reference

17 August 2017

2

1 reference

17 August 2017

249-257

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2405040

17 August 2017

0 references

cites work

Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Identification of natural killer cell receptor phenotypes associated with leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

HLA-G class I gene expression in normal and malignant hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Genomic polymorphism and allogeneic hematopoietic transplantation outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Licensing of natural killer cells by host major histocompatibility complex class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hematopoietic stem cells in healthy individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Novel approaches using natural killer cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The role of autologous natural killer cells in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Interleukin-2 and interleukin-15: immunotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Comparative expression of major histocompatibility complex (MHC) antigens on CD5+ and CD5- B cells in patients with chronic lymphocytic leukaemia (CLL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Lack of HLA-E surface expression is due to deficiency of HLA-E transcripts in the malignant hematopoietic cells of leukemic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Increased Infection-Related Mortality in KIR-Ligand???Mismatched Unrelated Allogeneic Hematopoietic Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Relevance of KIR gene polymorphisms in bone marrow transplantation outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2405040

1 reference

Dimensions Publication ID

17 August 2017

0 references

1 reference